Elevation Oncology, Inc.: Nasdaq/NYSE listing notice — Elevation Oncology receives Nasdaq bid-price deficiency notice; director resigns

Elevation Oncology, Inc.

Nasdaq notified on Sep 19, 2023 that bid price below $1.00 for 30 consecutive days; company has until Mar 18, 2024 to regain compliance.
To cure, closing bid must be at least $1.00 for 10 consecutive business days by Mar 18, 2024.
Director Colin Walsh resigned effective Sep 21, 2023 citing other professional opportunities; no disagreement with company.
Steven A. Elms appointed to fill Audit Committee vacancy left by Walsh's resignation.
Company considering actions to regain compliance; no assurance of success or continued listing.

item 3.01 item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Colin Walsh

Director

Elevation Oncology, Inc.

Effective: 2023-09-21
Filed: September 22, 2023, 7:59 PM ET

On September 21, 2023, Colin Walsh, Ph.D., notified the Company of his resignation from the Board of Directors of the Company (the "Board"), effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Elevation Oncology, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

September 19, 2023, Elevation Oncology, Inc. (the “Company”) received notice (the “Notice”) from the Listing Qualifications staff of the Nasdaq Stock Market LLC (“Nasdaq”) that, because the closing bid price for the Company’s common stock has fallen below $1.00 per share for 30 consecutive business days, the Company no longer complies with the minimum bid price requirement for continued listing on The Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1). The Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Global Select Market. Pursuant to N

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Colin Walsh resigned as Director at Elevation Oncology, Inc..

Action: resigned
Role: Director

Exact text from the filing

On September 21, 2023, Colin Walsh, Ph.D., notified the Company of his resignation from the Board of Directors of the Company (the "Board"), effective immediately.

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001558370-23-015947

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.